Goldline Pharmaceutical promoter and Managing Director Amol Laxmikant Mujumdar acquired 18,000 equity shares through an open market purchase on September 1, 2026. The transaction increased his stake in the Nagpur-based firm by 0.19%.

The acquisition was disclosed pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company has listed its shares on the BSE Limited.

Shareholding Details

Prior to this transaction, Mujumdar held 2,809,988 shares, representing 29.27% of the total paid-up share capital. None of these holdings were encumbered or pledged.

Following the purchase, his total holding stands at 2,827,988 shares, accounting for 29.46% of the voting capital. The total equity share capital of the company remains unchanged at 9,600,000 equity shares.

Regulatory Compliance

The disclosure was filed with the BSE Limited by Ruchi Sanket Modi, Company Secretary cum Compliance Officer. The filing confirms that the shares were acquired through the open market and no warrants or convertible securities were involved in the transaction.

Shareholders of Goldline Pharmaceutical approved all eight resolutions at its 22nd annual general meeting held on August 29, 2026. The vote included adopting financial statements for FY26 and authorizing material related-party transactions.

The meeting, convened in Nagpur, saw voting rights reckoned as of August 22, 2026. A total of 17 members cast votes representing 5,866,994 shares, accounting for approximately 61.11% of the outstanding shares. All resolutions secured unanimous support from the voting members, with zero votes cast against any agenda item.

Key Resolutions Passed

The shareholders approved several critical corporate actions through ordinary and special resolutions:

• Adoption of standalone and consolidated audited financial statements for the year ended March 31, 2026.
• Declaration of dividend on preference shares for FY26.
• Re-appointment of Mr. Prashant Shrikrishna Karkare as a director retiring by rotation.
• Approval of existing and new material related-party transactions with Activista Healthcare Private Limited, Nucleage Pharma Solutions Private Limited, and Numerius Healthcare Private Limited.

Capital Structure Changes

Two special resolutions required a higher majority threshold were also passed unanimously by those who voted:

1. Borrowing of unsecured loans from directors with an option of convertibility into equity shares.
2. Approval of loans, investments, guarantees, or security under Section 185 of the Companies Act, 2013.

What the Numbers Show

The voting data reveals a significant concentration of participation among promoter entities. While only 17 individual members cast valid votes, they represented over 58.6 lakh shares. Notably, for resolutions involving related-party transactions (Resolutions 4, 5, and 6), the promoter group's votes were marked as invalid due to conflict of interest, yet the resolutions still passed with 100% support from the remaining eligible public shareholders. This indicates strong alignment between the promoters and public investors on these strategic approvals, despite the regulatory requirement to exclude interested parties from the count.